Literature DB >> 19747113

Multiplexed fluorescence imaging of tumor biomarkers in gene expression and protein levels for personalized and predictive medicine.

Mark Q Smith1, Charles A Staley, David A Kooby, Toncred Styblo, William C Wood, Lily Yang.   

Abstract

Combining groundbreaking research and developments in cancer biomarkers, nanotechnology and molecular targeted medicine, a new realm of therapy is possible: personalized and predictive medicine. Developing a method to detect the overexpression of several tumor marker genes simultaneously, knowing that a single cell generally expresses more than one altered gene, should have a high predictive value for identifying cancer cells amidst the normal cellular background. Theoretically, a cancer's unique molecular profile can be used to predict its invasive and metastatic potential, its ability to evade immune surveillance, and its potential response to treatment. Fluorescent probes have been developed to detect the levels of expression of various biomarkers in tumor cells and tissues. Expression of biomarker messenger RNAs (mRNAs) or the presence of a specific mutation in an oncogene in cancer cells can be detected using molecular beacons (MBs) that only emit fluorescent signals after binding to its specific target mRNAs. Antibodies or ligands labeled with fluorophores or fluorescent quantum dots (QDs) have been successfully used to identify specific proteins expressed in cells. Furthermore, multiplex imaging using both MBs and antibodies labeled with a fluorescent probe on the same sample may provide important information correlating the level of mRNA expression and the subsequent level of protein production for a given biomarker. This technology will be useful in research investigating cancer biology, molecular imaging and molecular profiling. With the identification of biomarkers that are related to aggressive tumor types, we may be able to predict within certain patient populations who will develop invasive cancers, and what their prognosis will be given different treatment modalities, ultimately delivering medical care and treatment strategies that are specifically tailored to each individual patient, making personalized and predictive medicine a reality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747113      PMCID: PMC3594694          DOI: 10.2174/156652409789712765

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  52 in total

Review 1.  Molecular beacons: a novel DNA probe for nucleic acid and protein studies.

Authors:  W Tan; X Fang; J Li; X Liu
Journal:  Chemistry       Date:  2000-04-03       Impact factor: 5.236

Review 2.  Methods for visualizing RNA processing and transport pathways in living cells.

Authors:  R W Dirks; C Molenaar; H J Tanke
Journal:  Histochem Cell Biol       Date:  2001-01       Impact factor: 4.304

3.  Molecular beacons for detecting DNA binding proteins.

Authors:  Tomasz Heyduk; Ewa Heyduk
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

Review 4.  Luminescent quantum dots for multiplexed biological detection and imaging.

Authors:  Warren C W Chan; Dustin J Maxwell; Xiaohu Gao; Robert E Bailey; Mingyong Han; Shuming Nie
Journal:  Curr Opin Biotechnol       Date:  2002-02       Impact factor: 9.740

Review 5.  Breast cancer genetics: what we know and what we need.

Authors:  K L Nathanson; R Wooster; B L Weber; K N Nathanson
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

Review 6.  Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer.

Authors:  M A Rubin
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

7.  Delineation of prognostic biomarkers in prostate cancer.

Authors:  S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan
Journal:  Nature       Date:  2001-08-23       Impact factor: 49.962

8.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

9.  Tissue microarray sampling strategy for prostate cancer biomarker analysis.

Authors:  Mark A Rubin; Rodney Dunn; Myla Strawderman; Kenneth J Pienta
Journal:  Am J Surg Pathol       Date:  2002-03       Impact factor: 6.394

10.  p53-Dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy.

Authors:  Rishita Shah; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2004-09-21       Impact factor: 4.742

View more
  3 in total

Review 1.  Fluorescent imaging of cancerous tissues for targeted surgery.

Authors:  Lihong Bu; Baozhong Shen; Zhen Cheng
Journal:  Adv Drug Deliv Rev       Date:  2014-07-24       Impact factor: 15.470

2.  Comparison of fluorescence lifetime and multispectral imaging for quantitative multiplexing in biological tissue.

Authors:  Rahul Pal; Anand T N Kumar
Journal:  Biomed Opt Express       Date:  2022-06-09       Impact factor: 3.562

3.  Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease.

Authors:  Scott D Bringans; Jun Ito; Thomas Stoll; Kaye Winfield; Michael Phillips; Kirsten Peters; Wendy A Davis; Timothy M E Davis; Richard J Lipscombe
Journal:  EuPA Open Proteom       Date:  2017-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.